enGene Holdings Inc. (NASDAQ:ENGN) Receives $25.22 Consensus Target Price from Analysts

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have been assigned an average rating of “Buy” from the ten ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $25.22.

ENGN has been the topic of several research analyst reports. Piper Sandler assumed coverage on enGene in a research report on Tuesday, February 18th. They issued an “overweight” rating and a $26.00 price target on the stock. Morgan Stanley cut their price target on enGene from $37.00 to $34.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. JMP Securities restated a “market outperform” rating and issued a $18.00 price objective on shares of enGene in a research note on Monday, December 23rd. HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of enGene in a research note on Tuesday, March 11th. Finally, UBS Group lowered shares of enGene from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $34.00 to $7.00 in a research report on Friday, February 14th.

Institutional Investors Weigh In On enGene

Several institutional investors and hedge funds have recently made changes to their positions in ENGN. Vontobel Holding Ltd. bought a new position in enGene during the 4th quarter valued at about $69,000. Jane Street Group LLC bought a new position in shares of enGene in the fourth quarter valued at about $93,000. Toronto Dominion Bank bought a new stake in enGene during the 4th quarter worth about $97,000. Cubist Systematic Strategies LLC increased its position in enGene by 15.7% in the 4th quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock valued at $102,000 after acquiring an additional 2,080 shares in the last quarter. Finally, Corton Capital Inc. bought a new position in shares of enGene in the fourth quarter worth about $157,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Stock Up 0.4 %

ENGN opened at $5.15 on Friday. The firm has a market cap of $262.53 million, a P/E ratio of -8.88 and a beta of -0.61. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87. The business has a 50 day moving average price of $6.41 and a 200 day moving average price of $7.10. enGene has a twelve month low of $4.42 and a twelve month high of $18.40.

enGene (NASDAQ:ENGN) last posted its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. Research analysts forecast that enGene will post -1.56 EPS for the current year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.